{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:05:53Z","timestamp":1773115553571,"version":"3.50.1"},"reference-count":31,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer Netherlands"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1080\/13696998.2021.1997024","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T09:46:00Z","timestamp":1636451160000},"page":"1231-1239","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands"],"prefix":"10.1080","volume":"24","author":[{"given":"J. A.","family":"Spoorendonk","sequence":"first","affiliation":[{"name":"OPEN Health, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3925-7677","authenticated-orcid":false,"given":"J.-B.","family":"Briere","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-471X","authenticated-orcid":false,"given":"K.","family":"Bowrin","sequence":"additional","affiliation":[{"name":"Bayer Plc, Reading, Berkshire, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Millier","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Coppens","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tempelaar","sequence":"additional","affiliation":[{"name":"OPEN Health, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Verheggen","sequence":"additional","affiliation":[{"name":"OPEN Health, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.06.33"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht296"},{"issue":"25","key":"CIT0003","first-page":"e354\u2013471","volume":"126","author":"Fihn SD","year":"2012","journal-title":"Circulation"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.03.025"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"CIT0008","unstructured":"Federatie Medisch Specialisten. Richtlijn Cardiovasculair risicomanagement 2019. [cited 29 September 2020]. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/cardiovasculair_risicomanagement_cvrm\/samenvatting_cvr.html"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2014.04.020"},{"key":"CIT0010","unstructured":"Zorginstituut Nederland. GVS-advies rivaroxaban (Xarelto\u00ae) uitbreiding bijlage 2 voorwaarden 2019. [cited 29 September 2020]. Available from: https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2019\/03\/04\/gvs-advies-rivaroxaban-xarelto-uitbreiding-bijlage-2-voorwaarden"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021314"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz278"},{"key":"CIT0014","volume-title":"Nederland \u2013 Guideline for economic evaluations in healthcare","author":"Zorginstituut","year":"2016"},{"key":"CIT0015","unstructured":"National Institute for Health and Care Excellence (NICE). STA committee papers: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607\/ID1397) 2019. [cited 10 July 2020]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta607\/documents\/committee-papers"},{"key":"CIT0016","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) \u2013 Reimbursement review Rivaroxaban. Accessed from: https:\/\/www.cadth.ca\/rivaroxaban-6"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx658"},{"key":"CIT0018","volume-title":"Bijlage 1: Kostenhandleiding","author":"Roijen LH-v","year":"2016"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-013-0386-y"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-8-21"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10247"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724080-00005"},{"issue":"35","key":"CIT0023","first-page":"2911","volume":"168","author":"Heeg B","year":"2006","journal-title":"Ugeskrift for Laeger"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-1-2"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2000.2308"},{"issue":"28","key":"CIT0026","first-page":"1574","volume":"149","author":"Lamers LM","year":"2005","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00509.x"},{"key":"CIT0028","unstructured":"CBS Statline. Jaarmutatie consumentenprijsindex; vanaf 1963 2020. [updated 8 September 2020; cited 29 September 2020]. Available from: https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/70936ned\/table?ts=1525335961721"},{"key":"CIT0029","unstructured":"European Medicines Agency (EMA). Assessment report (EPAR) Xarelto, rivaroxaban 2018. [cited 29 September 2020]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/xarelto-h-c-944-ii-0058-epar-assessment-report-variation_en.pdf"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000052"},{"key":"CIT0031","unstructured":"Dorresteijn JAN, Visseren FLJ. The SMART risk score: The SMART risk score is a tool to estimate 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease: ESC; 2017. [updated 30 June 2017; cited 29 September 2020]. Available from: https:\/\/www.escardio.org\/Education\/ESC-Prevention-of-CVD-Programme\/Risk-assessment\/SMART-Risk-Score"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2021.1997024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T12:34:56Z","timestamp":1641386096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2021.1997024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["10.1080\/13696998.2021.1997024"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2021.1997024","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}